Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Plasmodium vivax and Plasmodium falciparum infection dynamics: re-infections, recrudescences and relapses.

White MT, Karl S, Koepfli C, Longley RJ, Hofmann NE, Wampfler R, Felger I, Smith T, Nguitragool W, Sattabongkot J, Robinson L, Ghani A, Mueller I.

Malar J. 2018 Apr 17;17(1):170. doi: 10.1186/s12936-018-2318-1.

2.

An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens.

Rodríguez-Galán A, Salman AM, Bowyer G, Collins KA, Longley RJ, Brod F, Ulaszewska M, Ewer KJ, Janse CJ, Khan SM, Hafalla JC, Hill AVS, Spencer AJ.

Sci Rep. 2017 Dec 5;7(1):17011. doi: 10.1038/s41598-017-17274-5.

3.

Naturally acquired antibody responses to more than 300 Plasmodium vivax proteins in three geographic regions.

Longley RJ, White MT, Takashima E, Morita M, Kanoi BN, Li Wai Suen CSN, Betuela I, Kuehn A, Sripoorote P, Franca CT, Siba P, Robinson LJ, Lacerda M, Sattabongkot J, Tsuboi T, Mueller I.

PLoS Negl Trop Dis. 2017 Sep 11;11(9):e0005888. doi: 10.1371/journal.pntd.0005888. eCollection 2017 Sep.

4.

Asymptomatic Plasmodium vivax infections induce robust IgG responses to multiple blood-stage proteins in a low-transmission region of western Thailand.

Longley RJ, França CT, White MT, Kumpitak C, Sa-Angchai P, Gruszczyk J, Hostetler JB, Yadava A, King CL, Fairhurst RM, Rayner JC, Tham WH, Nguitragool W, Sattabongkot J, Mueller I.

Malar J. 2017 Apr 28;16(1):178. doi: 10.1186/s12936-017-1826-8.

5.

The Threshold of Protection from Liver-Stage Malaria Relies on a Fine Balance between the Number of Infected Hepatocytes and Effector CD8+ T Cells Present in the Liver.

Spencer AJ, Longley RJ, Gola A, Ulaszewska M, Lambe T, Hill AV.

J Immunol. 2017 Mar 1;198(5):2006-2016. doi: 10.4049/jimmunol.1601209. Epub 2017 Jan 13.

6.

Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine.

Longley RJ, Halbroth BR, Salman AM, Ewer KJ, Hodgson SH, Janse CJ, Khan SM, Hill AVS, Spencer AJ.

Infect Immun. 2017 Feb 23;85(3). pii: e00641-16. doi: 10.1128/IAI.00641-16. Print 2017 Mar.

7.

High Efficacy of Primaquine Treatment for Plasmodium vivax in Western Thailand.

Longley RJ, Sripoorote P, Chobson P, Saeseu T, Sukasem C, Phuanukoonnon S, Nguitragool W, Mueller I, Sattabongkot J.

Am J Trop Med Hyg. 2016 Nov 2;95(5):1086-1089. Epub 2016 Sep 6.

8.

Changes in Serological Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection.

Hodgson SH, Llewellyn D, Silk SE, Milne KH, Elias SC, Miura K, Kamuyu G, Juma EA, Magiri C, Muia A, Jin J, Spencer AJ, Longley RJ, Mercier T, Decosterd L, Long CA, Osier FH, Hoffman SL, Ogutu B, Hill AV, Marsh K, Draper SJ.

Front Microbiol. 2016 Oct 13;7:1604. eCollection 2016.

9.

Insights into the naturally acquired immune response to Plasmodium vivax malaria.

Longley RJ, Sattabongkot J, Mueller I.

Parasitology. 2016 Feb;143(2):154-70. doi: 10.1017/S0031182015000670. Review.

PMID:
26864134
10.

Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PfUIS3, PfLSA1 and PfLSAP2 in Multiple Strains of Mice.

Longley RJ, Halbroth BR, Ewer KJ, Hill AV, Spencer AJ.

PLoS One. 2015 Dec 11;10(12):e0144515. doi: 10.1371/journal.pone.0144515. eCollection 2015.

11.

Acquisition and Longevity of Antibodies to Plasmodium vivax Preerythrocytic Antigens in Western Thailand.

Longley RJ, Reyes-Sandoval A, Montoya-Díaz E, Dunachie S, Kumpitak C, Nguitragool W, Mueller I, Sattabongkot J.

Clin Vaccine Immunol. 2015 Dec 9;23(2):117-24. doi: 10.1128/CVI.00501-15. Print 2016 Feb.

12.

Malaria vaccines: identifying Plasmodium falciparum liver-stage targets.

Longley RJ, Hill AV, Spencer AJ.

Front Microbiol. 2015 Sep 15;6:965. doi: 10.3389/fmicb.2015.00965. eCollection 2015. Review.

13.

Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates.

Longley RJ, Salman AM, Cottingham MG, Ewer K, Janse CJ, Khan SM, Spencer AJ, Hill AVS.

Sci Rep. 2015 Jul 3;5:11820. doi: 10.1038/srep11820.

14.

Development of an in vitro assay and demonstration of Plasmodium berghei liver-stage inhibition by TRAP-specific CD8+ T cells.

Longley RJ, Bauza K, Ewer KJ, Hill AV, Spencer AJ.

PLoS One. 2015 Mar 30;10(3):e0119880. doi: 10.1371/journal.pone.0119880. eCollection 2015.

15.

Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain.

Spencer AJ, Cottingham MG, Jenks JA, Longley RJ, Capone S, Colloca S, Folgori A, Cortese R, Nicosia A, Bregu M, Hill AV.

PLoS One. 2014 Jun 19;9(6):e100538. doi: 10.1371/journal.pone.0100538. eCollection 2014.

16.

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation.

Ewer KJ, O'Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, Goodman AL, Edwards NJ, Elias SC, Halstead FD, Longley RJ, Rowland R, Poulton ID, Draper SJ, Blagborough AM, Berrie E, Moyle S, Williams N, Siani L, Folgori A, Colloca S, Sinden RE, Lawrie AM, Cortese R, Gilbert SC, Nicosia A, Hill AV.

Nat Commun. 2013;4:2836. doi: 10.1038/ncomms3836.

17.

Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe.

Sheehy SH, Spencer AJ, Douglas AD, Sim BK, Longley RJ, Edwards NJ, Poulton ID, Kimani D, Williams AR, Anagnostou NA, Roberts R, Kerridge S, Voysey M, James ER, Billingsley PF, Gunasekera A, Lawrie AM, Hoffman SL, Hill AV.

PLoS One. 2013 Jun 18;8(6):e65960. doi: 10.1371/journal.pone.0065960. Print 2013.

18.

Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity.

Reyes-Sandoval A, Rollier CS, Milicic A, Bauza K, Cottingham MG, Tang CK, Dicks MD, Wang D, Longley RJ, Wyllie DH, Hill AV.

Mol Ther. 2012 Aug;20(8):1633-47. doi: 10.1038/mt.2012.25. Epub 2012 Feb 21.

Supplemental Content

Loading ...
Support Center